CN1152691C - 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 - Google Patents

使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 Download PDF

Info

Publication number
CN1152691C
CN1152691C CNB988118858A CN98811885A CN1152691C CN 1152691 C CN1152691 C CN 1152691C CN B988118858 A CNB988118858 A CN B988118858A CN 98811885 A CN98811885 A CN 98811885A CN 1152691 C CN1152691 C CN 1152691C
Authority
CN
China
Prior art keywords
antigen
application described
disease
cells
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988118858A
Other languages
English (en)
Chinese (zh)
Other versions
CN1306433A (zh
Inventor
F��W������
F·W·库尼
M·麦格拉斯
E·G·恩格莱曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nouveau Research Co Ltd
Original Assignee
Oxo Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie AG filed Critical Oxo Chemie AG
Publication of CN1306433A publication Critical patent/CN1306433A/zh
Application granted granted Critical
Publication of CN1152691C publication Critical patent/CN1152691C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB988118858A 1997-10-06 1998-10-06 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 Expired - Fee Related CN1152691C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6095397P 1997-10-06 1997-10-06
US60/060,953 1997-10-06
US60/060953 1997-10-06

Publications (2)

Publication Number Publication Date
CN1306433A CN1306433A (zh) 2001-08-01
CN1152691C true CN1152691C (zh) 2004-06-09

Family

ID=22032774

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988118858A Expired - Fee Related CN1152691C (zh) 1997-10-06 1998-10-06 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途

Country Status (12)

Country Link
US (4) US20050129784A1 (enExample)
EP (1) EP1021196B1 (enExample)
JP (1) JP4369615B2 (enExample)
CN (1) CN1152691C (enExample)
AT (1) ATE258799T1 (enExample)
AU (1) AU754928B2 (enExample)
CA (1) CA2306273A1 (enExample)
DE (1) DE69821506T2 (enExample)
DK (1) DK1021196T3 (enExample)
ES (1) ES2217582T3 (enExample)
PT (1) PT1021196E (enExample)
WO (1) WO1999017787A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148189A0 (en) * 1999-08-18 2002-09-12 Oxo Chemie Ag Chemically-stabilized chlorite solutions for treating cancer and other diseases
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
WO2008145376A1 (en) * 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN104519890A (zh) * 2012-01-19 2015-04-15 Ibt美国公司 四氯十氧(tcdo)的治疗应用
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
US11813234B2 (en) 2015-08-20 2023-11-14 Oxo Translational Science Gmbh Use of chlorite to treat red blood cell diseases and indications mediated thereby

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574084A (en) * 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
DE3515749A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5830511A (en) * 1992-06-25 1998-11-03 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
WO2008145376A1 (en) * 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

Also Published As

Publication number Publication date
AU754928B2 (en) 2002-11-28
EP1021196A2 (en) 2000-07-26
PT1021196E (pt) 2004-06-30
US20120141514A1 (en) 2012-06-07
DE69821506T2 (de) 2004-12-16
CN1306433A (zh) 2001-08-01
WO1999017787A3 (en) 1999-06-17
DE69821506D1 (de) 2004-03-11
CA2306273A1 (en) 1999-04-15
EP1021196B1 (en) 2004-02-04
US20110076344A1 (en) 2011-03-31
ATE258799T1 (de) 2004-02-15
AU9364298A (en) 1999-04-27
ES2217582T3 (es) 2004-11-01
JP4369615B2 (ja) 2009-11-25
JP2001518512A (ja) 2001-10-16
WO1999017787A2 (en) 1999-04-15
DK1021196T3 (da) 2004-06-07
US20090004295A1 (en) 2009-01-01
US20050129784A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US20110076344A1 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
Hommes et al. Anti-and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease
Kalechman et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels
CN1278739A (zh) 向皮肤抗原呈递细胞传递基因的方法
Lin et al. The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: a systematic review and meta-analysis
Cremel et al. Innovative approach in Pompe disease therapy: induction of immune tolerance by antigen-encapsulated red blood cells
CN1543338A (zh) 壳多糖微粒及其医疗用途
Mennini et al. Probiotics and other adjuvants in allergen-specific immunotherapy for food allergy: a comprehensive review
Myers et al. Interleukin‐12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long‐term antitumor immunity in syngeneic C3H mice
JPH10504304A (ja) ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
Leonard et al. Asthma: future directions
EP1408994A2 (en) Chemically-stabilized chlorite solutions for treating cancer
WO2024099363A1 (zh) Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用
Qian et al. Dysregulated luminal bacterial antigen‐specific T‐cell responses and antigen‐presenting cell function in HLA‐B27 transgenic rats with chronic colitis
WO2025025480A1 (zh) 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒
CN113905764B (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
Baron et al. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation
Pemmaraju et al. MPN-752: Efficacy of Pacritinib vs Momelotinib in Patients With Thrombocytopenic Myelofibrosis: A Matching Adjusted Indirect Treatment Comparison
US20220143081A1 (en) System and method of treating inflammatory lung diseases
Eddy et al. Differential pharmacodynamic changes of circulated immune subsets after treatment with abatacept or adalimumab in patients with anticitrullinated protein antibody-positive early rheumatoid arthritis in the AMPLIFIED study
Arruda et al. Inhibitors-Recent Insights
WO1996034612A1 (en) Compositions for the treatment of infections caused by hiv, aids and lymphomas using hydrogen peroxide
Di Caro et al. Tolerance and autoimmunity in type 1 diabetes
Coiffier et al. Romidepsin Induces Durable Responses in Relapsed/Refractory PTCL
Horwitz Commentary: Romidepsin for Previously Treated Patients With Peripheral or Aggressive T-Cell Lymphomas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: DIMISIDE LTD.

Free format text: FORMER NAME: OXO CHEMIE AG

CP01 Change in the name or title of a patent holder

Address after: Fribourg

Patentee after: Dimi Said Ltd

Address before: Fribourg

Patentee before: Oxo Chemie AG

C56 Change in the name or address of the patentee

Owner name: NOVO RESEARCH CO., LTD.

Free format text: FORMER NAME: DIMISIDE LTD.

CP01 Change in the name or title of a patent holder

Address after: Fribourg

Patentee after: Nouveau Research Co. Ltd.

Address before: Fribourg

Patentee before: Dimi Said Ltd

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040609

Termination date: 20141006

EXPY Termination of patent right or utility model